A Randomized, Open-labelled, Parallel, Phase 1 Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Hepatitis B Vaccine CVI-HBV-002 in Adults
Latest Information Update: 30 Nov 2023
At a glance
- Drugs CVI HBV-002 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Cha Vaccine Institute
- 30 Nov 2023 New trial record